Classical and pleiotropic actions of dipyridamole: Not enough light to illuminate the dark tunnel?

Pharmacological Research

Volumn 87, Issue , 2014, Pages 144-150

  Balakumar, Pitchai ^a   Nyo, Ying Hui ^a   Renushia, Raja ^a   Raaginey, Devarajan ^a   Oh, Ann Nah ^a   Varatharajan, Rajavel ^a   Dhanaraj, Sokkalingam A ^a  

^a AIMST UNIVERSITY   (Malaysia)

Author keywords

Antiplatelet agent; Dipyridamole; Pleiotropic actions; Therapeutic potentials

Indexed keywords

ACETYLSALICYLIC ACID; DIPYRIDAMOLE; ANTIINFLAMMATORY AGENT; ANTIOXIDANT; ANTITHROMBOCYTIC AGENT; PHOSPHODIESTERASE INHIBITOR; VASODILATOR AGENT;

ANTIARTHRITIC ACTIVITY; ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; ANTIPLATELET ACTIVITY; ARTHRITIS; CEREBROVASCULAR ACCIDENT; CLINICAL STUDY; COMBINATION CHEMOTHERAPY; DIABETIC NEPHROPATHY; DOSE RESPONSE; DRUG ACTIVITY; DRUG EFFICACY; DRUG SAFETY; HUMAN; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; REVIEW; RISK REDUCTION; SECONDARY PREVENTION; VASODILATORY ACTIVITY; ANIMAL; DIABETIC NEPHROPATHIES;

ANIMALS; ANTI-INFLAMMATORY AGENTS; ANTIOXIDANTS; DIABETIC NEPHROPATHIES; DIPYRIDAMOLE; HUMANS; PHOSPHODIESTERASE INHIBITORS; PLATELET AGGREGATION INHIBITORS; VASODILATOR AGENTS;

EID: 84907361812     PISSN: 10436618     EISSN: 10961186     Source Type: Journal    
DOI: 10.1016/j.phrs.2014.05.008     Document Type: Review

References (57)

1. S. Chakrabarti, and J.E. Freedman Dipyridamole, cerebrovascular disease, and the vasculature Vascul Pharmacol 48 2008 143 149
2. A. Melani, S. Cipriani, F. Corti, and F. Pedata Effect of intravenous administration of dipyridamole in a rat model of chronic cerebral ischemia Ann N Y Acad Sci 1207 2010 89 96
3. E. Ikeda, T. Kasai, K. Kajimoto, K. Miyauchi, N. Kubota, and T. Kurata et al. Dipyridamole therapy improves long-term survival after complete revascularization in patients with impaired cardiac function: a propensity analysis Circ J 72 2008 Oct 1588 1593
4. C.B. Pattillo, S.C. Bir, B.G. Branch, E. Greber, X. Shen, and S. Pardue et al. Dipyridamole reverses peripheral ischemia and induces angiogenesis in the Db/Db diabetic mouse hind-limb model by decreasing oxidative stress Free Radic Biol Med 50 2011 262 269
5. P.K. Venkatesh, C.B. Pattillo, B. Branch, J. Hood, S. Thoma, and S. Illum et al. Dipyridamole enhances ischaemia-induced arteriogenesis through an endocrine nitrite/nitric oxide-dependent pathway Cardiovasc Res 85 2010 661 670
6. C.D. d'Esterre, K.M. Tichauer, R.I. Aviv, W. Eisert, and T.Y. Lee Dipyridamole treatment prior to stroke onset: examining post-stroke cerebral circulation and outcome in rabbits Transl Stroke Res 2 2011 186 194
7. H.H. Kim, and J.K. Liao Translational therapeutics of dipyridamole Arterioscler Thromb Vasc Biol 28 2008 s39 s42
8. S. Yip, and O. Benavente Antiplatelet agents for stroke prevention Neurotherapeutics 8 2011 475 487
9. P. Verro, P.B. Gorelick, and D. Nguyen Aspirin plus dipyridamole versus aspirin for prevention of vascular events after stroke or TIA: a meta-analysis Stroke 39 2008 1358 1363
10. P.H. Halkes, L.J. Gray, P.M. Bath, H.C. Diener, B. Guiraud-Chaumeil, and F.M. Yatsu et al. Dipyridamole plus aspirin versus aspirin alone in secondary prevention after TIA or stroke: a meta-analysis by risk J Neurol Neurosurg Psychiatry 79 2008 1218 1223
11. J. Greenhalgh, A. Bagust, A. Boland, C. Martin Saborido, J. Oyee, and M. Blundell et al. Clopidogrel and modified-release dipyridamole for the prevention of occlusive vascular events (review of Technology Appraisal No. 90): a systematic review and economic analysis Health Technol Assess 15 2011 1 178
12. E.L. De Schryver, A. Algra, and J. van Gijn Dipyridamole for preventing stroke and other vascular events in patients with vascular disease Cochrane Database Syst Rev 3 2007 CD001820
13. D.W. Dippel, L. Maasland, P. Halkes, L.J. Kappelle, P.J. Koudstaal, and A. Algra Prevention with low-dose aspirin plus dipyridamole in patients with disabling stroke Stroke 41 2010 2684 2686
14. A.S. Weyrich, E.J. Skalabrin, and L.W. Kraiss Targeting the inflammatory response in secondary stroke prevention: a role for combining aspirin and extended-release dipyridamole Am J Ther 16 2009 164 170
15. M.A. Sloan Aspirin plus extended-release dipyridamole and clopidogrel were similarly effective for preventing recurrent stroke Evid Based Med 14 2009 46 47
16. N. Crown, and T. Mysak Safety of fixed-dose aspirin-extended-release dipyridamole in patients with ischemic heart disease Am J Health Syst Pharm 67 2010 728 733
17. L. Arnarsdottir, C. Hjalmarsson, L. Bokemark, and B. Andersson Comparative evaluation of treatment with low-dose aspirin plus dipyridamole versus aspirin only in patients with acute ischaemic stroke BMC Neurol 12 2012 67
18. X. Li, G. Zhou, X. Zhou, and S. Zhou The efficacy and safety of aspirin plus dipyridamole versus aspirin in secondary prevention following TIA or stroke: a meta-analysis of randomized controlled trials J Neurol Sci 332 2013 92 96
19. V.E. Held, M.E. Wolf, and M.G. Hennerici Antithrombotic therapy in transient ischemic attack patients Front Neurol Neurosci 33 2014 147 161
20. D.L. Bhatt, K.A. Fox, W. Hacke, P.B. Berger, H.R. Black, and W.E. Boden et al. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events N Engl J Med 354 2006 1706 1717
21. H.C. Diener, J. Bogousslavsky, L.M. Brass, C. Cimminiello, L. Csiba, and M. Kaste et al. Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients (MATCH): randomised, double-blind, placebo-controlled trial Lancet 364 2004 331 337
22. ESPRIT Study Group P.H. Halkes, J. van Gijn, L.J. Kappelle, P.J. Koudstaal, and A. Algra Aspirin plus dipyridamole versus aspirin alone after cerebral ischemia of arterial origin (ESPRIT): randomised controlled trial Lancet 367 2006 1665 1673
23. A.S. Weyrich, M.M. Denis, J.R. Kuhlmann-Eyre, E.D. Spencer, D.A. Dixon, and G.K. Marathe et al. Dipyridamole selectively inhibits inflammatory gene expression in platelet-monocyte aggregates Circulation 111 2005 633 642
24. M. Massaro, E. Scoditti, M.A. Carluccio, M. Pellegrino, N. Calabriso, and C. Storelli et al. Dipyridamole decreases inflammatory metalloproteinase-9 expression and release by human monocytes Thromb Haemost 109 2013 280 289
25. S. Guo, M. Stins, M. Ning, and E.H. Lo Amelioration of inflammation and cytotoxicity by dipyridamole in brain endothelial cells Cerebrovasc Dis 30 2010 290 296
26. M.M. Soliman, and M.M. Arafah Treatment with dipyridamole improves cardiac function and prevent injury in a rat model of hemorrhage Eur J Pharmacol 678 2012 26 31
27. B.P. Ramakers, N.P. Riksen, T.H. Stal, S. Heemskerk, P. van den Broek, and W.H. Peters et al. Dipyridamole augments the antiinflammatory response during human endotoxemia Crit Care 15 2011 R289
28. A. Gomaa, M. Elshenawy, N. Afifi, E. Mohammed, and R. Thabit Influence of dipyridamole and its combination with NO donor or NO synthase inhibitor on adjuvant arthritis Int Immunopharmacol 10 2010 1406 1414
29. S. Sloka, L.M. Metz, W. Hader, Y. Starreveld, and V.W. Yong Reduction of microglial activity in a model of multiple sclerosis by dipyridamole J. Neuroinflammation 10 2013 89
30. S. Chakrabarti, P. Blair, C. Wu, and J.E. Freedman Redox state of dipyridamole is a critical determinant for its beneficial antioxidant and antiinflammatory effects J Cardiovasc Pharmacol 50 2007 449 457
31. W.G. Eisert Dipyridamole in antithrombotic treatment Adv Cardiol 47 2012 78 86
32. G. Tanzilli, C. Greco, V. Pasceri, F. Pelliccia, A. Arrivi, and A. Placanica et al. Dipyridamole versus verapamil for treatment of no-reflow during primary angioplasty Catheter Cardiovasc Interv 76 2010 787 793
33. T. Saino, T. Misaki, M. Matsuura, T. Shikanai, and Y. Satoh Dipyridamole inhibits intracellular calcium transients in isolated rat arteriole smooth muscle cells Arch Histol Cytol 71 2008 235 247
34. S.B. Zhuplatov, T. Masaki, D.K. Blumenthal, and A.K. Cheung Mechanism of dipyridamole's action in inhibition of venous and arterial smooth muscle cell proliferation Basic Clin Pharmacol Toxicol 99 2006 431 439
35. T.H. Chen, C.F. Chang, S.C. Yu, J.C. Wang, C.H. Chen, and P. Chan et al. Dipyridamole inhibits cobalt chloride-induced osteopontin expression in NRK52E cells Eur J Pharmacol 613 2009 10 18
36. M.S. Hsieh, W.B. Zhong, S.C. Yu, J.Y. Lin, W.M. Chi, and H.M. Lee Dipyridamole suppresses high glucose-induced osteopontin secretion and mRNA expression in rat aortic smooth muscle cells Circ J 74 2010 1242 1250
37. P. Balakumar, and N.K. Sharma Healing the diabetic heart: does myocardial preconditioning work Cell Signal 24 2012 53 59
38. P. Balakumar, and L. Babbar Preconditioning the hyperlipidemic myocardium: fact or fantasy Cell Signal 24 2012 589 595
39. A. Boutros, and J. Wang Ischemic preconditioning, adenosine and bethanechol protect spontaneously hypertensive isolated rat hearts J Pharmacol Exp Ther 275 1995 1148 1156
40. R.D. Lasley, and R.M. Mentzer Jr. Protective effects of adenosine in the reversibly injured heart Ann Thorac Surg 60 1995 843 846
41. H. Wasir, A. Bhan, S.K. Choudhary, R. Sharma, S. Chauhan, and P. Venugopal Pretreatment of human myocardium with adenosine Eur J Cardiothorac Surg 19 2001 41 46
42. R. Germack, and J.M. Dickenson Adenosine triggers preconditioning through MEK/ERK1/2 signalling pathway during hypoxia/reoxygenation in neonatal rat cardiomyocytes J Mol Cell Cardiol 39 2005 429 442
43. J. Yang, and L.H. Li Adenosine preconditioning reduces myocardial injury in patients undergoing off-pump coronary artery bypass grafting surgery Zhonghua Yi Xue Za Zhi 87 2007 2313 2315
44. N.K. Sharma, N. Mahadevan, and P. Balakumar Adenosine transport blockade restores attenuated cardioprotective effects of adenosine preconditioning in the isolated diabetic rat heart: potential crosstalk with opioid receptors Cardiovasc Toxicol 13 2013 22 32
45. Y. Ye, B. Long, J. Qian, J.R. Perez-Polo, and Y. Birnbaum Dipyridamole with low-dose aspirin augments the infarct size-limiting effects of simvastatin Cardiovasc Drugs Ther 24 2010 391 399
46. Y. Ye, Y. Lin, R. Perez-Polo, M.H. Huang, M.G. Hughes, and D.J. McAdoo et al. Enhanced cardioprotection against ischemia-reperfusion injury with a dipyridamole and low-dose atorvastatin combination Am J Physiol Heart Circ Physiol 293 2007 813 818
47. M. Soliman Nucleoside transport inhibitor, dipyridamole, induced myocardial protection following hemorrhagic shock in ex vivo perfused rat hearts J Saudi Heart Assoc 23 2011 75 80
48. A.H. Hopper, H. Tindall, and J.A. Davies Administration of aspirin-dipyridamole reduces proteinuria in diabetic nephropathy Nephrol Dial Transplant 4 1989 140 143
49. P. Khajehdehi, J. Roozbeh, and H. Mostafavi A comparative randomized and placebo-controlled short-term trial of aspirin and dipyridamole for overt type-2 diabetic nephropathy Scand J Urol Nephrol 36 2002 145 148
50. T. Aizawa, S. Suzuki, T. Asawa, M. Komatsu, S. Shigematsu, and N. Okada et al. Dipyridamole reduces urinary albumin excretion in diabetic patients with normo- or microalbuminuria Clin Nephrol 33 1990 130 135
51. A.K. Sharma, D. Khanna, and P. Balakumar Low-dose dipyridamole treatment partially prevents diabetes mellitus-induced vascular endothelial and renal abnormalities in rats Int J Cardiol 172 2014 530 532
52. P.H. Halkes, J. van Gijn, L.J. Kappelle, P.J. Koudstaal, A. Algra European/Australasian Stroke Prevention in Reversible Ischaemia Trial Study Group Risk indicators for development of headache during dipyridamole treatment after cerebral ischaemia of arterial origin J Neurol Neurosurg Psychiatry 80 2009 437 439
53. J. Lökk Dipyridamole-associated headache in stroke patients - interindividual differences Eur Neurol 62 2009 109 113
54. L.C. Becker Conditions for vasodilator-induced coronary steal in experimental myocardial ischemia Circulation 57 1978 1103 1110
55. J. Ando, H. Yasuda, T. Kobayashi, A. Miyamoto, K. Kanamori, and R. Murakami et al. Conditions for coronary steal caused by coronary vasodilator in man Jpn Heart J 23 1982 79 95
56. T. Chiba, and K. Umegaki Pivotal roles of monocytes/macrophages in stroke Mediators Inflamm 2013 2013 759103
57. E. Eeckhout, and M.J. Kern The coronary no-reflow phenomenon: a review of mechanisms and therapies Eur Heart J 22 2001 729 739